Biocept, Inc.’s Liquid Biopsy Lung Cancer Target Selector Assay To Be Featured At World Conference On Lung Cancer
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that clinical data from a study conducted with researchers at the University of California, San Diego’s Moores Cancer Center indicate that Biocept’s lung cancer Target Selector™ assay has high concordance with tumor status in patients with metastatic lung cancer. The clinical data will be presented in a poster presentation at the International Association of Lung Cancer’s 16th World Conference on Lung Cancer in Denver on September 8, 2015.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.